Agenus (AGEN) Competitors $4.82 -0.34 (-6.59%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. ZBIO, MYGN, RIGL, EBS, VSTM, XOMA, VNDA, LXRX, CDXS, and ACHVShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), Codexis (CDXS), and Achieve Life Sciences (ACHV). These companies are all part of the "biotechnology" industry. Agenus vs. Its Competitors Zenas Biopharma Myriad Genetics Rigel Pharmaceuticals Emergent BioSolutions Verastem XOMA Vanda Pharmaceuticals Lexicon Pharmaceuticals Codexis Achieve Life Sciences Zenas Biopharma (NASDAQ:ZBIO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends. Is ZBIO or AGEN more profitable? Zenas Biopharma has a net margin of 0.00% compared to Agenus' net margin of -145.89%. Company Net Margins Return on Equity Return on Assets Zenas BiopharmaN/A N/A N/A Agenus -145.89%N/A -85.68% Do analysts prefer ZBIO or AGEN? Zenas Biopharma currently has a consensus price target of $36.67, suggesting a potential upside of 223.91%. Agenus has a consensus price target of $14.00, suggesting a potential upside of 190.46%. Given Zenas Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Zenas Biopharma is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Agenus 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger valuation & earnings, ZBIO or AGEN? Zenas Biopharma has higher earnings, but lower revenue than Agenus. Zenas Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZenas Biopharma$15M31.57-$148.51M-$3.55-3.19Agenus$99.52M1.33-$245.76M-$8.67-0.56 Does the MarketBeat Community prefer ZBIO or AGEN? Agenus received 465 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 68.37% of users gave Agenus an outperform vote. CompanyUnderperformOutperformZenas BiopharmaOutperform Votes4100.00% Underperform VotesNo VotesAgenusOutperform Votes46968.37% Underperform Votes21731.63% Does the media prefer ZBIO or AGEN? In the previous week, Zenas Biopharma had 9 more articles in the media than Agenus. MarketBeat recorded 24 mentions for Zenas Biopharma and 15 mentions for Agenus. Agenus' average media sentiment score of 0.77 beat Zenas Biopharma's score of -0.01 indicating that Agenus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agenus 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ZBIO or AGEN? 61.5% of Agenus shares are held by institutional investors. 16.5% of Zenas Biopharma shares are held by company insiders. Comparatively, 5.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryZenas Biopharma beats Agenus on 11 of the 16 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.15M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-0.4332.9027.2119.96Price / Sales1.33466.20408.49157.63Price / CashN/A168.6838.2534.64Price / Book-0.623.427.074.69Net Income-$245.76M-$72.35M$3.23B$248.14M7 Day Performance-18.99%2.59%0.68%0.91%1 Month Performance42.60%20.47%9.59%5.71%1 Year Performance-69.88%-17.11%32.02%14.71% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus4.2176 of 5 stars$4.82-6.6%$14.00+190.5%-71.5%$132.15M$99.52M-0.43440Gap DownZBIOZenas Biopharma1.3209 of 5 stars$10.06+5.7%$36.67+264.5%N/A$420.85M$15M-2.83N/ATrending NewsHigh Trading VolumeMYGNMyriad Genetics4.2015 of 5 stars$4.46+6.4%$14.79+231.5%-78.0%$411.11M$831.30M-3.432,600High Trading VolumeRIGLRigel Pharmaceuticals3.3162 of 5 stars$20.15+4.9%$36.40+80.6%+113.0%$360.12M$203.08M143.94160Positive NewsAnalyst RevisionEBSEmergent BioSolutions4.152 of 5 stars$6.30-0.3%$14.33+127.5%+4.6%$341.95M$930.30M-1.542,420VSTMVerastem3.2347 of 5 stars$6.02-19.9%$13.63+126.3%+65.2%$330.79M$10M-1.8950Positive NewsHigh Trading VolumeXOMAXOMA4.234 of 5 stars$24.22-2.2%$69.50+187.0%-1.6%$289.84M$13.05M-6.9610Positive NewsVNDAVanda Pharmaceuticals4.7101 of 5 stars$4.30-0.9%$16.50+283.7%-21.8%$253.42M$201.35M-13.44290Positive NewsAnalyst RevisionLXRXLexicon Pharmaceuticals2.6994 of 5 stars$0.62-0.8%$3.67+489.9%-63.6%$224.70M$31.21M-0.83140Positive NewsCDXSCodexis3.9721 of 5 stars$2.25-2.2%$8.00+255.6%-31.8%$186.40M$49.82M-2.59250Positive NewsAnalyst RevisionACHVAchieve Life Sciences2.2373 of 5 stars$3.90+8.9%$14.33+267.5%-36.4%$135.27MN/A-3.4520High Trading Volume Related Companies and Tools Related Companies Zenas Biopharma Alternatives Myriad Genetics Alternatives Rigel Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Verastem Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Lexicon Pharmaceuticals Alternatives Codexis Alternatives Achieve Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
